These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 25917338)

  • 1. The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer.
    Chen Z; Chen N; Shen P; Gong J; Li X; Zhao T; Liao B; Liu L; Liu Z; Zhang X; Liu J; Peng Z; Chen X; Xu M; Gui H; Zhang P; Wei Q; Zhou Q; Zeng H
    Prostate; 2015 Sep; 75(12):1247-54. PubMed ID: 25917338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
    Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
    Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
    Yamamoto A; Kato M; Hattori K; Naito Y; Tochigi K; Sano T; Kawanishi H; Ishikawa T; Yuba T; Hattori R; Gotoh M; Tsuzuki T
    BJU Int; 2020 May; 125(5):702-708. PubMed ID: 31833179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Wang Z; Zhu S; Zhao J; Nie L; Chen X; Zhang M; Chen N; Sun G; Chen J; Ni Y; Dai J; Liu Z; Tao R; Zhang X; Zhu X; Zhang H; Liang J; Wang Z; He B; Shen P; Zeng H
    Prostate; 2021 Nov; 81(15):1191-1201. PubMed ID: 34435696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
    Zhao T; Liao B; Yao J; Liu J; Huang R; Shen P; Peng Z; Gui H; Chen X; Zhang P; Zhu Y; Li X; Wei Q; Zhou Q; Zeng H; Chen N
    Prostate; 2015 Feb; 75(3):225-32. PubMed ID: 25307858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
    Kim KB; Jo JK; Ahn S; Lee S; Jeong SJ; Hong SK; Byun SS; Lee SE
    Korean J Urol; 2015 Aug; 56(8):580-6. PubMed ID: 26279827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
    Porter LH; Hashimoto K; Lawrence MG; Pezaro C; Clouston D; Wang H; Papargiris M; Thorne H; Li J; ; Ryan A; Norden S; Moon D; Bolton DM; Sengupta S; Frydenberg M; Murphy DG; Risbridger GP; Taylor RA
    BJU Int; 2018 Jun; 121(6):971-978. PubMed ID: 28977728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
    Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
    BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
    Lavoie JM; Zou K; Khalaf D; Eigl BJ; Kollmannsberger CK; Vergidis J; Noonan K; Zulfiqar M; Finch D; Chi KN
    Prostate; 2019 Feb; 79(3):281-287. PubMed ID: 30370697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
    Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy.
    Zhao J; Shen P; Sun G; Chen N; Liu J; Tang X; Huang R; Cai D; Gong J; Zhang X; Chen Z; Li X; Wei Q; Zhang P; Liu Z; Liu J; Zeng H
    Oncotarget; 2017 Aug; 8(33):55374-55383. PubMed ID: 28903426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.